Calls for papers
-
Vistagen has announced that the Phase 3 PALISADE-3 study of intranasal fasedienol for the treatment of social anxiety disorder failed to meet its primary endpoint, with fasedienol failing to demonstrate a statistically significant reduction of… Read more . . .
-
According to Asia Scientific Global, the FDA has cleared an IND that will allow a Phase 1 trial of its Beta1 inhaled dry powder therapy for the treatment of erectile dysfunction to move forward, and… Read more . . .
-
Tiziana Life Sciences has announced the initiation of a Phase 2 trial of intranasal foralumab in patients with early-stage Alzheimer’s disease. In June 2024, Tiziana said that it had received approval for the use of… Read more . . .
-
Lee’s Pharmaceutical Holdings subsidiary Nova Pneuma has acquired inhaled drug delivery technology and other assets developed by Alexza Pharmaceuticals, the company said. Alexza merged with Grupo Ferrer in 2016. The deal, which is expected to close… Read more . . .
-
Savara has announced two new European patents covering Molbreevi molgramostim inhalation solution. The company said that it has received notification from the European Patent Office that it intends to grant a patent covering the liquid… Read more . . .
-
Milestone Pharmaceuticals announced that the FDA has approved Cardamyst etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) and that the company expects to launch the product in early 2026. Milestone submitted the NDA… Read more . . .
-
CDMO Intertek announced that it has acquired a 29,000 sq ft facility in Melbourn, UK, which will allow the company to add to its GMP manufacturing capacity for inhaled drug products. The facility, which is… Read more . . .
-
Nebulizer maker HCMed, in partnership with several other OINDP-related organizations, has organized a new pitch day called RespireX that will debut in March 2026. Aimed at providing early stage start-ups or academic groups with support… Read more . . .
-
Amneal Pharmaceuticals announced that the FDA has approved the company’s ANDA for a generic version of Teva’s ProAir HFA albuterol MDI for the treatment of asthma. Amneal submitted the ANDA in 2023 and was sued… Read more . . .
-
US-based start-up CorriXR Therapeutics has announced a partnership with inhaled drug developer InhaTarget Therapeutics and device developer Merxin Ltd for development of an inhaled gene therapy for the treatment of lung cancer. InhaTarget will use its lipid… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK